{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:40:18Z","timestamp":1792669218613,"version":"4.5.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Substantial improvement in prognosis among metastatic renal cell carcinoma (mRCC) patients has been achieved, owing to the rapid development and utilization of immunotherapy. In particular, immune checkpoint inhibitors (ICIs) have been considered the backbone of systemic therapy for patients with mRCC alongside multi-targeted tyrosine kinase inhibitors (TKIs) in the latest clinical practice guidelines. However, controversies and challenges in optimal individualized treatment regarding immunotherapy remains still About 2\/3 of the patients presented non-response or acquired resistance to ICIs. Besides, immune-related toxicities, namely immune-related adverse events, are still elusive and life-threatening. Thus, reliable biomarkers to predict immunotherapeutic outcomes for mRCC patients are needed urgently. Tumor microenvironment (TME), consisting of immune cells, vasculature, signaling molecules, and extracellular matrix and regulates tumor immune surveillance and immunological evasion through complex interplay, plays a critical role in tumor immune escape and consequently manipulates the efficacy of immunotherapy. Various studied have identified the different TME components are significantly associated with the outcome of mRCC patients receiving immunotherapy, making them potential valuable biomarkers in therapeutic guidance. The present review aims to summarize the latest evidence on the associations between the components of TME including immune cells, cytokines and extracellular matrix, and the therapeutic responses among mRCC patients with ICI-based treatment. We further discuss the feasibility and limitation of these components as biomarkers.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1146738","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T05:49:35Z","timestamp":1686116975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiaming","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.3390\/ijms21134691","article-title":"Immune checkpoint inhibitors in the treatment of renal cancer: current state and future perspective","volume":"21","author":"Lavacchi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S240889","article-title":"Immunotherapeutic targets and therapy for renal cell carcinoma","volume":"9","author":"Sepe","year":"2020","journal-title":"Immunotargets Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00117","article-title":"RNA-Seq of liver from pigs divergent in feed efficiency highlights shifts in macronutrient metabolism, hepatic growth and immune response","volume":"10","author":"Horodyska","year":"2019","journal-title":"Front Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.3390\/ijms231810948","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review","volume":"23","author":"Cozma","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103240118","article-title":"Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004206","article-title":"Single-cell transcriptomics reveals a low CD8(+) T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma","volume":"10","author":"Peng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","article-title":"Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma","volume":"12","author":"Phillips","year":"2021","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","article-title":"Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures","volume":"17","author":"Senbabaoglu","year":"2016","journal-title":"Genome Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","article-title":"Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma","volume":"39","author":"Au","year":"2021","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70241-3","article-title":"Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials","volume":"13","author":"Tran","year":"2012","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.773063","article-title":"CD248(+) cancer-associated fibroblasts: a novel prognostic and therapeutic target for renal cell carcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41419-022-05059-2","article-title":"SMOC2 promotes an epithelial-mesenchymal transition and a pro-metastatic phenotype in epithelial cells of renal cell carcinoma origin","volume":"13","author":"Feng","year":"2022","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2386","article-title":"Predictive biomarkers of overall survival in patients with metastatic renal cell carcinoma treated with IFNalpha +\/- bevacizumab: results from CALGB 90206 (Alliance)","volume":"28","author":"Nixon","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i8.541","article-title":"Combination drug regimens for metastatic clear cell renal cell carcinoma","volume":"11","author":"Khetani","year":"2020","journal-title":"World J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1900887","article-title":"Combination therapy as first-line treatment in metastatic renal-cell carcinoma","volume":"380","author":"Escudier","year":"2019","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02014-7","article-title":"Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study","volume":"27","author":"Tamada","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0745","article-title":"Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale","volume":"15","author":"Grunwald","year":"2019","journal-title":"Future Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0043","article-title":"NCCN guidelines insights: kidney cancer, version 1.2021","volume":"18","author":"Motzer","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4337","article-title":"Treatment selection in first-line metastatic renal cell carcinoma-the contemporary treatment paradigm in the age of combination therapy: a review","volume":"8","author":"Navani","year":"2022","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Kumar","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.3390\/cancers14205005","article-title":"Treatment of refractory metastatic renal cell carcinoma","volume":"14","author":"Vento","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","volume":"16","author":"Diaz-Montero","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00490","article-title":"Targeting the tumor microenvironment in renal cell cancer biology and therapy","volume":"9","author":"Heidegger","year":"2019","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.3390\/cells10113231","article-title":"From bench to bedside: how the tumor microenvironment is impacting the future of immunotherapy for renal cell carcinoma","volume":"10","author":"Anker","year":"2021","journal-title":"Cells"},{"key":"B46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002949","article-title":"CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma","volume":"9","author":"Klumper","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001506","article-title":"Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC","volume":"9","author":"Ross-Macdonald","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004803","article-title":"Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood","volume":"10","author":"Carlisle","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14812","article-title":"Determining programmed cell death ligand 1 expression in circulating tumor cells of patients with clear cell renal cell carcinoma and its correlation with response to programmed cell death protein 1 inhibitors","volume":"29","author":"Chen","year":"2022","journal-title":"Int J Urol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1832348","DOI":"10.1080\/2162402X.2020.1832348","article-title":"Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions","volume":"9","author":"Incorvaia","year":"2020","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3206","article-title":"irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial","volume":"25","author":"Pignon","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0972","article-title":"Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade","volume":"27","author":"Terry","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0282-3","article-title":"Checkpoint inhibitor immunotherapy in kidney cancer","volume":"17","author":"Xu","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.10.007","article-title":"Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation","volume":"53","author":"Paver","year":"2021","journal-title":"Pathology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/jcm8050743","article-title":"Expression of PD-1 and CTLA-4 are negative prognostic markers in renal cell carcinoma","volume":"8","author":"Kahlmeyer","year":"2019","journal-title":"J Clin Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1038\/s41467-021-25865-0","article-title":"Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy","volume":"12","author":"Takamatsu","year":"2021","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4149\/neo_2014_006","article-title":"Prognostic implication of TIM-3 in clear cell renal cell carcinoma","volume":"61","author":"Yuan","year":"2014","journal-title":"Neoplasma"},{"key":"B68","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1838141","DOI":"10.1080\/2162402X.2020.1838141","article-title":"Tumor-infiltrating TNFRSF9(+) CD8(+) T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response","volume":"9","author":"Li","year":"2020","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1038\/s41598-020-63060-1","article-title":"Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma","volume":"10","author":"Kawashima","year":"2020","journal-title":"Sci Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001823","article-title":"Intratumoral CXCL13(+)CD8(+)T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma","volume":"9","author":"Dai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02563-2","article-title":"Tumor-infiltrating CD39(+)CD8(+) T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients","volume":"69","author":"Qi","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122092","article-title":"T Cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma","volume":"3","author":"Hopkins","year":"2018","journal-title":"JCI Insight"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32145","article-title":"Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer","volume":"145","author":"Liu","year":"2019","journal-title":"Int J Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1862948","DOI":"10.1080\/2162402X.2020.1862948","article-title":"Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma","volume":"10","author":"Kato","year":"2021","journal-title":"Oncoimmunology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4900","article-title":"IL-8 induces the epithelial-mesenchymal transition of renal cell carcinoma cells through the activation of AKT signaling","volume":"12","author":"Zhou","year":"2016","journal-title":"Oncol Lett"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.3390\/cancers14235985","article-title":"High serum levels of IL-6 predict poor responses in patients treated with pembrolizumab plus axitinib for advanced renal cell carcinoma","volume":"14","author":"Sang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0873-9","article-title":"IL-8 and cancer prognosis on immunotherapy","volume":"26","author":"Bakouny","year":"2020","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12032-019-1255-3","article-title":"Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer","volume":"36","author":"Ozawa","year":"2019","journal-title":"Med Oncol"},{"key":"B84","article-title":"Serum IL-6 as a marker of disease progression in interstitial nephritis","volume":"14","author":"Shen","year":"2022","journal-title":"Am J Transl Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.007","article-title":"The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis","volume":"76","author":"Abdel Galil","year":"2015","journal-title":"Cytokine"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.5876","article-title":"Correlation between serum inflammatory factors TNF-alpha, IL-8, IL-10 and henoch-schonlein purpura with renal function impairment","volume":"15","author":"Yuan","year":"2018","journal-title":"Exp Ther Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.04.034","article-title":"MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer","volume":"39","author":"Hashmi","year":"2021","journal-title":"Urol Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B89","doi-asserted-by":"publisher","first-page":"9846","DOI":"10.1038\/s41598-017-10134-2","article-title":"The oncogenic role of COL23A1 in clear cell renal cell carcinoma","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.03.029","article-title":"Cellular hyaluronan is associated with a poor prognosis in renal cell carcinoma","volume":"38","author":"Jokelainen","year":"2020","journal-title":"Urol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-161","article-title":"Assessment of the prognostic value of SPOCK1 in clear cell renal cell carcinoma: a bioinformatics analysis","volume":"11","author":"Chen","year":"2022","journal-title":"Transl Androl Urol."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.220046","article-title":"Novel ligand for integrin alpha2beta1 in the epidermis","volume":"286","author":"Veit","year":"2011","journal-title":"J Biol Chem"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2019.10429","article-title":"Linking myofibroblast generation and microvascular alteration: the role of CD248 from pathogenesis to therapeutic target (Review)","volume":"20","author":"Di Benedetto","year":"2019","journal-title":"Mol Med Rep"},{"key":"B94","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.3390\/cancers14174072","article-title":"The extracellular matrix environment of clear cell renal cell carcinoma","volume":"14","author":"Oxburgh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1457","article-title":"The diagnostic, prognostic, and therapeutic potential of adaptive immune receptor repertoire profiling in cancer","volume":"80","author":"Cowell","year":"2020","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","article-title":"T-Cell repertoire diversity: friend or foe for protective antitumor response","volume":"41","author":"Porciello","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.692142","article-title":"Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis","volume":"11","author":"Kartikasari","year":"2021","journal-title":"Front Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s40425-019-0819-2","article-title":"Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK\/PD analysis in patients with renal cell carcinoma","volume":"7","author":"Wang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.575569","article-title":"The extracellular matrix-derived biomarkers for diagnosis, prognosis, and personalized therapy of malignant tumors","volume":"10","author":"Petersen","year":"2020","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1146738\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T05:49:39Z","timestamp":1686116979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1146738\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2023.1146738"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1146738","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"article-number":"1146738"}}